If you have been reading about Albumin conjugation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-24. Numbers and descriptions here follow the published literature rather than marketing material.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
=== SELDI-TOF-MS === Samples spotted on a SELDI surface are typically analyzed using time-of-flight mass spectrometry. An irradiating laser ionizes peptides from crystals of the sample/matrix mixture. The matrix absorbs the energy of the laser pulse, preventing destruction of the molecule, and transfers charge to the sample molecules, forming ions. The ions are then briefly accelerated through an electric potential and travel down a field-free flight tube where they are separated by their velocity differences. The mass-to-charge ratio of each ion can be determined from the length of the tube, the kinetic energy given to ions by the electric field, and the velocity of the ions in the tube. The velocity of the ions is inversely proportional to the square root of the mass-to-charge ratio of the ion; ions with low mass-to-charge ratios are detected earlier than ions with high mass-to-charge ratios.
When the analytical concentration of methylamine is twice that of ethylenediamine and the concentration of copper is the same in both reactions, the concentration [Cu(en)]2+ is much higher than the concentration [Cu(MeNH2)2]2+ because β11 ≫ β12. The difference between the two stability constants is mainly due to the difference in the standard entropy change, ΔS⊖. In the reaction with the chelating ligand there are two particles on the left and one on the right, whereas in equation with the monodentate ligand there are three particles on the left and one on the right. This means that less entropy of disorder is lost when the chelate complex is formed than when the complex with monodentate ligands is formed. This is one of the factors contributing to the entropy difference. Other factors include solvation changes and ring formation. Some experimental data to illustrate the effect are shown in the following table.
==== Decoy DNA delivery ==== Decoy DNA is an exogenous double-strand DNA (dsDNA), which can mimic a promoter sequence that can inhibit the activity of a specific transcription factor. But dsDNA has the same problem as other therapeutics, poor bioavailability. In one study, CPPs TP and TP10 were coupled to NFкB decoy DNA, which blocked the effect of interleukin-1-induced NFкB activation and IL-6 gene expression. In another study, TP10 coupled Myc decoy DNA decreased proliferative capacity of N2a cells.
S. divinorum (0.89 mg/g to 3.70 mg/g). S. recognita (212.9 μg/g). S. cryptantha (51.5 μg/g). S. glutinosa (38.9 μg/g). Salvinorin B has been detected in S. potentillifolia and S. adenocaulon, however these species do not contain a measureable amount of salvinorin A.
=== Medical === Dihydromorphine is used for the management of moderate to severe pain such as that occurring in cancer; however, it is less effective in treating neuropathic pain and is generally considered inappropriate and ineffective for psychological pain.
Sources: en.wikipedia.org
==== Exercise ==== Exercise can reduce weight. Weight training has been recommended as a type of exercise to burn fat, because of its ability to increase muscle mass, which increases metabolism. Both long-term exercise programs and anti-obesity medications reduce abdominal fat volume.
=== Generic names === Trazodone is the generic name of the drug and its INNTooltip International Nonproprietary Name, BANTooltip British Approved Name, and DCFTooltip Dénomination Commune Française, while trazodone hydrochloride is its USANTooltip United States Adopted Name, USPTooltip United States Pharmacopeia, BANMTooltip British Approved Name, and JANTooltip Japanese Accepted Name.
According to Pino Arlacchi, the former head of the UN Office on Drugs and Crime, the portrayal of Venezuela as a "drug state" is a "geopolitically motivated smear campaign" by the US government; he refers to the World Drug Report 2025 and his own experience, according to which the Venezuelan government's cooperation in the fight against drug trafficking is among the best in South America. According to Arlacchi, the US has taken an interest in Venezuelan oil reserves, which are among the largest in the world. The International Federation for Human Rights (FIDH) in the Americas demands an immediate cessation of aggression against Venezuela. The U.S. government's instrumentalisation of the "fight against drugs" conveys a disproportionate use of force and sets a dangerous precedent. Russia and China reiterated their condemnation of US actions against Venezuela at an emergency UN Security Council meeting on 23 December. Russia's Foreign Ministry called the deployment "excessive military force" and spokesperson Maria Zakharova stated that Russia "confirms our firm support for the Venezuelan leadership in defending its national sovereignty". On 19 November 2025, Chinese foreign ministry spokesperson Mao Ning said that China opposes "any interference in Venezuela's internal affairs under any pretext" and called on the United States to "choose a course of action conducive to peace and stability".
== History == The first miP was discovered during a research in the early 1990s on genes for basic helix–loop–helix (bHLH) transcription factors from a murine erythroleukaemia cell cDNA library. The protein was an inhibitor of DNA binding (ID protein), and negatively regulated the transcription factor complex. The protein was 16 kDa and consisted of a helix-loop-helix (HLH) domain. The microprotein formed bHLH/HLH heterodimers that disrupted the functional basic helix–loop–helix (bHLH) homodimers. The first plant microprotein discovered was the LITTLE ZIPPER (ZPR) protein. The LITTLE ZIPPER protein contains a leucine zipper domain, but lacks the domains required for DNA binding and transcription activation. Thus, LITTLE ZIPPER protein is analogous to the ID protein. Although not all proteins are small, in 2011, this class of protein was given the name microproteins because their negative regulatory actions are similar to those of miRNAs. The ID protein or proteins similar to ID are found in all animals. Plant microproteins are only found in higher orders. However, the homeodomain transcription factors that belong to the three-amino-acid loop-extension (TALE) family are targets of microproteins, and these homeodomain proteins are conserved in animals, plants, and fungi.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.